Mipletamig Shows Strong Clinical Activity in Frontline AML, With 85% Remission Rate and Favorable Safety Profile
DENVER, Colo., Jun 18, 2025 (247marketnews.com)- Aptevo Therapeutics (NASDAQ:APVO) announced compelling new data from its ongoing Phase 1b/2 RAINIER trial...